{"id":"NCT02083783","sponsor":"Tris Pharma, Inc.","briefTitle":"TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHD)","officialTitle":"TRI102 in the Treatment of Children With Attention Deficit Hyperactivity Disorder (ADHA): A Laboratory Classroom Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2014-10","completion":"2014-12","firstPosted":"2014-03-11","resultsPosted":"2020-08-26","lastUpdate":"2020-08-26"},"enrollment":108,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Disorder With Hyperactivity"],"interventions":[{"type":"DRUG","name":"TRI102","otherNames":["amphetamine extended-release oral suspension"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"TRI102","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether TRI102 is effective in the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children ages 6-12.","primaryOutcome":{"measure":"SKAMP (Swanson, Kotkin, Agler, M-Flynn, and Pelham Scale)","timeFrame":"Absolute change from baseline in SKAMP-C score from baseline to 4 hours after dose","effectByArm":[{"arm":"TRI102","deltaMin":-9.1,"sd":7.51},{"arm":"Placebo","deltaMin":5.6,"sd":7.85}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"6 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":5,"countries":["United States"]},"refs":{"pmids":["36730749"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":52},"commonTop":["Abdominal pain, upper","Epistaxis","Rhinitis, allergic"]}}